Watson Confirms Welchol Patent Challenge (WPI)

Watson Pharmaceuticals WPI today confirmed that its subsidiary, Watson Laboratories, filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Colesevelam HCI 625 mg tablets. Watson's Colesevelam HCI tablets are a generic version of Daiichi Sankyo Welchol.